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Abstract  
Background: There are an increasing number of older housebound patients who are not seen by the 
pharmacists responsible for the provision of their medications. This growing population is 
increasingly dependent on time-limited carers for their medication support. 
Objectives: To evaluate the findings of pharmacist led holistic domiciliary medicine use reviews 
(dMUR) targeted at this group of housebound patients, in terms of required medication support and 
the identification of unmet social care needs.  
Methods: Patients were identified in the London Borough of Richmond (UK) who were 
predominantly housebound and taking multiple medications. Twelve community pharmacists visited 
patients and carried out interviews as part of a structured holistic dMUR, which included 
understanding the patients’ living conditions. 
Results: Altogether 133 patients completed the dMUR with the pharmacist. Patients had a mean age 
of 81.7 years (range 49-98 years) and took an average of 9.4 different medications, 3 of which being 
high risk. Nearly 40% had difficulties taking their medications, including a lack of dexterity or 
difficulty swallowing. Over a quarter (26.8%) of diabetic patients lacked monitoring. Patients were 
identified with a risk of falling (14.3%) and inadequate social care (11.3%). Continence, dehydration, 
hygiene and nutrition issues were found, often caused by mobility problems or a lack of suitable 
toilet facilities. A need for home modifications such as hand rails to prevent falls was also identified.  
Conclusions: This study highlighted the varied difficulties facing housebound patients identified 
during the pharmacists’ visits, including a lack of social care provision and fall hazards. Domiciliary 
visits by pharmacists may be able to help identify the diverse care needs of isolated housebound 
patients helping to integrate their care requirements.   
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ACEI -Angiotensin Converting Enzyme Inhibitors 4 
ADR – Adverse Drug Reaction 5 
CCCG – Croydon Clinical Commissioning Group 6 
dMUR – Domiciliary Medicine Use Review  7 
GP- General Practioner 8 
HCP – Health Care Professional   9 
INR - International Normalised Ratio 10 
LIMOS- Lewisham Integrated Medicines Optimisation Service  11 
MDS- Monitored Dosage System 12 
MUR - Medicine Use Review 13 
NOACs – New Oral Anti-Coagulant 14 
NSAID – Non-Steroidal Anti Inflammatory Drug  15 
PDVS- Pharmacist Domiciliary Visiting Services  16 
UTI – Urinary Tract Infection 17 
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Introduction:  21 
The Medicine Use Review (MUR) scheme introduced in the UK in 2005 [1]  enabled community 22 
pharmacists to further support patients in the use of their medications. MUR provides an 23 
opportunity for a pharmacist and patient to discuss any problems and answer questions a patient 24 
may have using their medication.  Domiciliary Medicine Use Reviews (dMURs) are a means of 25 
reaching a group of patients who would otherwise be unable to benefit from an MUR at their 26 
community pharmacy or through a telephone review.  Although the need for domiciliary reviews 27 
was originally addressed in the early 2000s through the Pharmacist Domiciliary Visiting Services 28 
(PDVS), [2,3], it has been the success of the dMUR pilot in Croydon during 2011/2012 [4,5], that 29 
encouraged the provision of similar services such as those in West Yorkshire [6],  North Wales [7], 30 
Exeter [8,9], and the London boroughs of Wandsworth [10] and Lewisham [11]. The latter scheme, 31 
Lewisham Integrated Medicines Optimisation Service (LIMOS), supports high-risk patients with 32 
referrals from both primary and secondary care, encouraging the involvement of all stakeholders in 33 
patient care. Many schemes claim success in saving money, positive patient feedback and 34 
prevention of readmissions through pharmacists resolving problems [4, 7, 9,12]. The 2005 Homer 35 
trial [13] was initiated specifically to study whether domiciliary medicine reviews could reduce 36 
hospital readmissions in older people  (>80 years) population. Hospital pharmacists provided post-37 
discharge education and support to patients in their medical conditions and the use of their 38 
medications. Recently discharged patients received up to 2 visits from the pharmacist within 2 39 
weeks and 8 weeks after discharge and were monitored for 6 months. The study outcomes included 40 
30% of the intervention group being readmitted and requiring 43% more GP visits than the control 41 
group. Explanations for these results included that the discussions with the pharmacist made 42 
patients more aware of the warning signs of deterioration or previously non-adherent patients 43 
started to take their medications causing previously avoided iatrogenic illnesses.  A concurrent study 44 
by Salter [14] analysed some of the pharmacists’ interactions with patients during the dMUR, 45 
highlighting the lack of spontaneity and joint purpose of the interaction. Pharmacists were keen to 46 
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gather precise information from patients who were often defensive against any suggestion that they 47 
could not manage their medicines or were forgetful. The POLYMED study [15] also investigated 48 
whether non-elective hospital admissions could be prevented by a domiciliary pharmacist providing 49 
medicine reviews for older patients. In addition to two visits, the pharmacist also met regularly with 50 
the GP to discuss changes to the patients’ medications. Although this intervention resulted in a 51 
decrease in medications prescribed, there was no difference in hospital admissions. 52 
A driving force for dMUR is the growth in older people; the number of over 90s in the UK is expected 53 
to triple between 2010 and 2035 [16].  A consequence will be an increase in the number of 54 
housebound patients with chronic conditions, requiring the provision of cost effective services able 55 
to support patients remaining in their own homes and successfully managing their medications. A 56 
growing number of older people are living alone, whilst medication and social support available from 57 
family members is decreasing [17]. Relatives may find it stressful trying to manage the medications, 58 
especially if a patient has dementia and/or difficulty swallowing medication. Adherence issues and 59 
polypharmacy are common in older people, with an estimated 16.3% patients taking between 5-9 60 
different medications [18].  A German study of domiciliary medicine reconciliation of older people 61 
found over a quarter of the medications found in patients‘ homes were undocumented. [19] It is 62 
estimated that over 5% of hospital admissions are due to adverse drug reactions (ADR) in the UK [20] 63 
and Spain [21]. Medicine optimisation can be achieved by holistically reviewing a patient’s 64 
medications and understanding their use based on individual circumstances [22].  Polypharmacy is 65 
also associated with a greater risk of prescribing errors [23] which may be uncovered by such 66 
reviews.  Older patients’ multiple needs are best addressed by a co-ordinated and integrated 67 
approach to care. Integrated care may be understood as the co-ordination of the delivery of patient 68 
care connecting the clinical aspects of the health care system with other service providing systems 69 
such as social care, working together with the aim of improving patient care [24,25]. Instead of 70 
having a narrow single disease focused view, with each co-morbidity being  managed independently, 71 
disregarding social and other underlying causes of ill health [25], the overall wellbeing of a patient 72 
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should be considered. This patient focused approach is what Valentijn, [25] call the micro level of 73 
clinical integration.  74 
The 2011 census showed that 13.5% (25,200) of people in the London borough of Richmond were ≥ 75 
65 years, ranking it the joint 6
th
 borough out of 32 in London in terms of its older population. Holistic 76 
dMUR were carried out by community pharmacists in Richmond-Upon-Thames and analysed to 77 
understand how patients’ complex needs may be supported by community pharmacists and 78 
whether they can help to integrate medical and social care requirements of older housebound 79 
patients. This forms the aim of the study.   80 
Method  81 
The design of the dMUR and selection of both pharmacists and patients invited to 82 
participate is summarised in Table 1. 83 
Selection of pharmacists for 
the scheme 
Community pharmacy contractors who had completed MUR 
training in the London Borough of Richmond were invited by the 
Kingston and Richmond Local Pharmaceutical Committee 
(K&RLPC), to take part in a new dMUR service.   
Training provided to the 
pharmacists 
Information sessions were given by trainers from Croydon Clinical 
Commissioning Group (CCCG)[4,5]. 
The comprehensive nature of the dMURs was explained and the 
areas the pharmacist needed to cover discussed in detail.  
Criteria for patient inclusion The main criteria for patient inclusion were being predominantly 
housebound and receiving delivery of their medications from the 
pharmacy.  Suspected non-compliant patients were prioritised, 
together with those prescribed multiple or frequently changing 
medications and patients with a long-term condition such as a 
respiratory condition or diabetes. Agreement was established 
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with the patients’ general practitioner (GP), a few patients were 
also referred by their GP. 
Support for the pharmacists Pharmacists were supported by GPs and reported any problems 
or issues back to the patients’ GPs. 
 Design of the dMUR The comprehensive dMUR form was designed in collaboration 
with CCCG to collect information about many aspects of the 
patients’ medication and home and included a checklist. The 
dMUR form was comprised of the following sections (see 
appendix A for the complete dMUR form)   
• List of all medication including herbal and over the 
counter (OTC) medications and supplements 
• Access to medications, delivery, running out medication 
• Physical issues – storage, ability to administer medication 
• Cognitive issues – Awareness of time, adherence 
• Clinical issues – Side effects, symptoms 
• Beliefs about medications – Understanding their 
condition 
• General housekeeping – Maintenance, mobility 
• Social issues – Meals, trip hazards, toilet facilities 
• Medication for disposal 
• Carer communication form 
• Brief feedback  
Table 1 Description of the dMUR scheme 84 
A telephone call was made to prospective participants to explain the purpose of the dMUR and to 85 
arrange a convenient time for the pharmacist to visit the patient’s home. The pharmacist asked if a 86 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
member of the patient’s family or carer could be present. During the visit the pharmacist asked to 87 
see the patient’s medications and to look around the house using the checklist to ensure all areas 88 
were covered as per the dMUR form. 89 
After the completion of five dMUR, the forms were monitored for completeness by the pharmacist 90 
service lead and guidance given where necessary, this helped to ensure the uniformity of the dMUR. 91 
Pharmacists were then invited to carry out further dMUR to a maximum of fifteen. The pharmacists’ 92 
visits took place between May 2015 and January 2016. At the end of the study the responses were 93 
anonymised and entered into Microsoft Excel and analysed using descriptive statistics. This study 94 
was considered a service evaluation and hence there was no need for ethical approval. 95 
 96 
Results 97 
A total of 134 patients were visited by 12 different community pharmacists, with the carer or family 98 
member contributing to the dMUR when necessary. The numbers of patients visited by each 99 
pharmacist varied between 5 and 15. All of dMUR forms were completed, with only 1 being 100 
incomplete and thus not included in the study. Each dMUR visit took between 30 and 45 minutes to 101 
complete, depending on circumstances of the patient.  The majority (67.1%) of the patients visited 102 
were female (Table 2), with a median age of 83 years. Over a quarter of the patients had a paid carer 103 
to support them. A total of 401 problems or issues were recorded by the pharmacists, with 83 issues 104 
identified as social and 318 as medicine related. 105 
 106 
Demographics n (%) n =133 
Female 82 (61.7) 
Male 39 (29.3)  
Not reported 12 (9.0) 
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Mean age 
Median age 
81.7 years 
83 years 
Age range 49-98 years 
Existing Care Provision   
Paid Carer 34 (25.6) 
Partner 16 (12.0) 
Other family 24 (18.0) 
Other: Neighbour/friend 2(1.5) 
Table 2 Demographic data 107 
Polypharmacy was widespread, with an average of 9.4 different drugs taken by each patient (Table 108 
3), an average of nearly 3 of these drugs were classed as high risk and associated with increased 109 
hospital admissions (NSAIDs, beta-blockers, diuretics, warfarin and NOACs, ACEI, anti-depressants, 110 
opiates, digoxin, prednisolone, clopidogrel [20]). Over 60% of patients (n=80) were taking at least 111 
one analgesic medication and 15% (n= 20) were taking a combination opioid such as co-codamol. 112 
The number of patients taking medicines for mental health conditions was high (n=52, 39%), with 25 113 
patients taking anti-depressants and 11 patients taking more than one anti-depressant, “Z” drug 114 
(zolpidem or zopiclone), or benzodiazepine. Nearly a quarter of patients (n=33, 24.8%) were taking 115 
an anticholinergic drug or one with anti-cholinergic burden e.g. amitriptyline 9.7% (n= 13). Nearly 116 
one-third (31.6%) were receiving support with administering at least one medication. 117 
Medication Number 
Mean number of drugs taken 9.4 
Number of drugs taken: Range 1 to 23 
Mean number of high risk drugs taken  2.9 
Number of high risk drugs taken: Range 0-9 
Total receiving help taking medications  42 (31.6%) 
Family member 9 (6.8%) 
Partner 12 (9.0%) 
Carer 21 (15.8%) 
Table 3 Number of medications taken by patients and support in administration 118 
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A wide range of medication related issues were identified (table 4). Nearly 20% (17.3%) of patients 119 
had recently run out of a medication. A significant number of patients had physical difficulties taking 120 
their medication (n=52, 39.1%), with the reasons identified including a lack of dexterity in opening a 121 
blister, applying eyedrops or using inhalers and difficulties in swallowing medications. A patient with 122 
respiratory disease had been without inhaled steroids for several months as she could not use the 123 
prescribed inhaler.  124 
 Patients’ medication regime could sometimes be simplified, for example by advising patients to take 125 
a medication previously taken separately with the rest of their medications.  A monitored dosage 126 
system (MDS) was offered when a patient was confused or was struggling to manage their 127 
medications or reminder alarms were also suggested if appropriate.  128 
Many clinical issues were identified, over a quarter (27.8%) of patients reported both preventable 129 
and potentially dangerous side effects (table 4). Additionally, over 10% of patients were suffering 130 
from pain, but had not always reported this to their GP. Diabetic patients and those taking warfarin 131 
were not being regularly monitored due to being housebound.   132 
Patients were often concerned about taking one or more of their medications (28.6%), especially 133 
when they were taking >10 mediations.  134 
Two houses were found to be damp and one was cluttered with cables crossing the floor posing a 135 
tripping hazard. Over 10% of patients had unaddressed mobility problems in their homes (n=16, 136 
12.0%), requiring a bath lift to enable them to safely use the bath or extra hand rails on the stairs. 137 
One patient was unable to access toilet on the first floor, with problematic access to an outside 138 
ground level toilet with a zimmer frame. Another was unable to use their zimmer frame to reach the 139 
bathroom due to a lack of space. The lack of mobility also caused patients to be unable to look after 140 
themselves and perform housekeeping tasks, which led to poor diet and hygiene.   141 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
Tripping hazards, such as ill-fixed rugs and cluttered walkways were highlighted to the patient or 142 
carer. There were safety concerns about a confused patient using their gas hob. Several patients felt 143 
they were putting on weight or were constipated due to the meals they received which were not 144 
their choice. Two diabetic patients were advised to cut down on sweet food at the day centre due to 145 
increasing blood sugar levels.  146 
Several cases of unmet social care issues were identified: A patient said they had carer, but they 147 
stopped coming; one partner caregiver was noted to be “overwhelmed in his role as caregiver”; a 148 
lack of provision of care meant two patients were only able to receive their eye drops when care 149 
givers were present; the pharmacist was able to demonstrate to one carer how to administer eye 150 
drops to the patient. One patient was not eating cooked meals, her daughter left sandwiches in 151 
fridge which contained uneaten out of date food; three patients were worried about falling on way 152 
to the toilet, so did not drink enough and suffered from urinary tract infections (UTI). A patient’s 153 
family and pharmacist were concerned about the lack of adherence, additionally the patient’s 154 
nutrition was inadequate and ways of improving this was discussed. 155 
Over one-third of patients (n=52, 39.1%,) had unwanted medications for disposal, ranging from 1 to 156 
20 different types of medications. One pharmacist reported on a dMUR “There were meds 157 
everywhere”. Some patients had stockpiled a drug, others were no longer taking a medication, but 158 
had not informed the pharmacy. A patient was prescribed a Clenil inhaler but was unable to use 159 
them, as she could only use nebules, resulting in 3 wasted unused inhalers. 160 
Over one-third (n=47, 35.3%), of dMUR visits resulted in contact with the patient’s GP, this varied 161 
from referral for potential medication change to advising the GP a patient is no longer taking a 162 
medication. 163 
Issues Found by Pharmacists Grouped by Section of dMUR n (%) 
Access to medication Issues 23 
Patients recently run out of a medication 
Examples: After hospital discharge, a patient was halving their dose of 
metformin, so they did not run out. Drugs which are not supplied in MDS.   
23 (17.3) 
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Physical Issues 96 
Difficulty opening their medications 15 (11.3)  
Difficulty administering drug/ inhaler/eye drops 52 (39.1) 
Difficulty reading labels -large print labels provided 13 (10) 
Medications not stored properly e.g. Medications stored in box near 
window in direct sunlight 
8 (6.0) 
Patient having problems instilling eye drops due to shaky hands.   
Example: A patient only received eye drops when carer was present 
8 (6.0) 
Cognitive Issues 58 
Timing issues: 
Examples: Patient was forgetting to take lansoprazole as it was labelled to 
be taken separately from the rest of the medications at breakfast.  
A patient was forgetting to take atorvastatin at night as it was the only 
medication taken in the evening. 
31 (23.3) 
 
New MDS suggested (Patients with existing MDS 36.1% n=48)  27 (20.3) 
Clinical Issues 98 
Side Effect Management 37 (27.8) 
Examples: Swollen ankles from taking calcium channel blockers. Opioid 
induced constipation.  A patient experiencing nose bleeds and bruising 
who was taking both aspirin and venlafaxine, Patient with diarrhoea taking 
a milk-based food supplement 
 
Pain control issues 18 (13.5) 
Examples: Co-codamol was not controlling pain from a recent fall. 
Patient suffering severe shoulder pain for over a week and not reporting it. 
 
Patients with old or dirty spacers requiring replacing 3 (2.3) 
Taking the medication in the wrong way 14 (10.5) 
Examples: Patient taking isosorbide mononitrate at 12 hourly intervals 
which could cause tolerance. Patient taking simvastatin at lunch time 
 
Inadequate Monitoring 13 (9.8) 
Examples: Glucose not checked in patients with diabetes (n=8/30), patient 
taking digoxin not monitored for a long time (n=1/12), International 
Normalised Ratio(INR) not recently checked in patients taking warfarin 
(n=4/56) 
 
Patient no longer needs medication or needs dose reduction 13 (10.0) 
Example: Patients did not need carbocysteine or omeprazole anymore.  
Beliefs about medications 43 
Worried about medication or condition. Examples: Patients concerned 
about aspirin causing a bleed, patients worried about running out of 
medicines, Patients were worried they were taking too many tablets. 
38 (28.6) 
Patient does not think their medication(s) are working 5 (3.8) 
General Housekeeping / Social Care Issues  83 
Damp unmaintained housing issues 2 (1.5) 
Patients were recommended to be reassessed by an occupational therapist 
due to concerns with their zimmer frame use.  
3 (2.3) 
Patient bedridden or struggling to move around home 11 (8.3) 
Pharmacist concerned about patient falling – often with unfixed carpets 
and rugs being identified as trip hazards.  
Example: Patient had suffered a fall during the 3 months prior to the 
dMUR. The flat was dirty, cluttered with an unlevel floor, increasing a risk 
of more falls. Nothing was done to tidy the flat or level the floor to 
19 (14.3) 
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decrease the risk of falls. 
Hand rails/ bathroom aid required 16 (12.0) 
Concern about nutrition – Example some patients did not have access to 
hot food. 
9 (6.8) 
Concern about inadequate hydration 8 (6.0) 
New carer need identified - for example patients unable to wash without 
help 
15 (11.3) 
 
Medication for disposal 
Examples: 400 co-codamaol: Patient stockpiling 
45 temazepam: Expired 
1 patient had 20 different medications: Expired and no longer used 
52 (39.1) 
Patients or carers finding the dMUR helpful 133 (100%) 
Table 4: Issues highlighted by the dMURs 164 
 165 
Table 4: Issues highlighted by the dMURs 166 
Discussion  167 
This study using dMUR led by community pharmacists gave an insight into patients’ lives, allowing a 168 
comprehensive understanding of the home environment, care, and medication taken by mostly 169 
older and housebound people in the London Borough of Richmond. A wide range of issues were 170 
highlighted including new social care needs, potential safety hazards, inadequate hydration and 171 
nutrition and difficulties administering medication.  172 
Polypharmacy was common, and it was apparent from the medication lists that many patients had 173 
multiple-morbidities.  Medication was not optimised with patients suffering from side effects, 174 
inadequate analgesia and adherence problems, the latter often due to physical problems resulting 175 
from loss of dexterity or lack of carer support.   Patients taking warfarin and patients with diabetes 176 
were not always monitored appropriately. NOACs may be considered, removing the need for INR 177 
checking[26]; however, with no INR checking, any non-adherence may go unnoticed for longer. 178 
Nearly a quarter of patients were taking anticholinergic drugs or drugs with anticholinergic burden,  179 
with their increased side effects of confusion and postural hypotension in the older people [27] 180 
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contributing to frailty and increasing the risk of falls [28]. The use of anticholinergics should be 181 
questioned and monitored in older people [27].  182 
Over 10% of patients were dependent on their partners for support in medicines administration. 183 
Partners may find this role stressful, often being of similar age to the patient, unwell themselves, 184 
and therefore incapable of safely performing this task [29].  Over 25% of patients received help from 185 
a paid carer, who often helped in medication administration.  It is recognised that paid carers will 186 
play an increasing role in all aspects of patients’ medications [29]; however, there is a lack of 187 
information concerning the safe administration of medications in a domiciliary setting [30], carers 188 
may not have the necessary skills nor time to perform these tasks.  Pharmacists are well placed to 189 
advise and support carers on all medication issues [8] and the dMUR provided an opportunity for the 190 
pharmacists to do this. There may be pressure from social care agencies for patients to use MDS 191 
[11,31]. Although the appropriateness of MDS was not assessed in this study, other adherence 192 
support may be more appropriate, and the pharmacists were able to suggest alternative solutions, 193 
such as simplifying the medication regime, explaining the importance of taking medications or 194 
suggesting the use of reminder alarm and large print labels. Nearly 40% of patients had unused 195 
medicines removed, this was higher than some studies [33], [34] . 196 
Although over 40% of patients had existing mobility problems, the dMUR highlighted that these 197 
were not always adequately addressed, patients had problems with zimmer frames, lack of hand 198 
rails, tripping hazards such as clutter and unfixed rugs were pointed out to carers. Over 10% of 199 
patients required more care than they were receiving. The interwoven nature of some patients’ 200 
problems was highlighted in this study by patients with continence and mobility issues with a fear of 201 
falling when mobilising to the bathroom. These patients were avoiding drinking, causing recurrent 202 
UTI and the need for antibiotics. An integrated solution is required which provides mobility 203 
incontinence and social care assessment. The need for integrated care was emphasised in The King’s 204 
Fund report [32] with reference to the growing numbers of patients with co-morbidities and 205 
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polypharmacy.  Patients’ concerns and treatment aims need to be listened to, understood and 206 
placed at the centre of decision making [25]. Especially when considering very old patients, decisions 207 
concerning their medications should involve discovering what is important to them, rather than 208 
simply trying to encourage all medication adherence. A compromise is needed between the desire 209 
for the best clinical solutions and the personal choices of patients who need to cope with the drug 210 
regime [32].  Good clinical and interpersonal skills are required to successfully achieve this. The 211 
LIMOS service, involves hospital pharmacists who have developed excellent communications, not 212 
only with patients but with other HCP, charities and care providers [11]. There may be a lack of 213 
awareness of the services and advice which community pharmacists can provide and increasing 214 
collaboration with social care would benefit all parties. Additionally, it is essential to increase 215 
pharmacists’ local knowledge to refer to voluntary services or other supporting services.  However, 216 
establishing such links can take time to develop [11]. The dMUR role could improve and evolve to 217 
bridge the gaps in care as highlighted by this study. However, for this to happen, key areas such as 218 
increased collaboration with social care, improved communication skills and enhanced clinical 219 
knowledge need to be addressed.   220 
Study Strengths and Limitations 221 
The study would have benefited from an independent evaluation of patients’ satisfaction. Although 222 
It was not part of the remit for the dMUR to investigate the patient’s social connections, this would 223 
have provided an important understanding of patients’ family and social support networks and may 224 
have enabled signposting to relevant organisations. Access to patients’ full medical records would 225 
have provided a more complete understanding of their medical situation. Consented recordings of 226 
the dMUR may have allowed improvement of the patient/pharmacist interactions. Service referrals 227 
were predominantly made through doctors, with more time and training the pharmacists could have 228 
performed this task themselves. 229 
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A strength of this study was its comprehensive nature which was able to provide an understanding 230 
of the difficulties faced by this increasingly large sector of the population. Community pharmacists 231 
are known for their medication knowledge, but this study showed pharmacists may be capable of 232 
integrating different aspects of patient care and needs. 233 
Conclusion  234 
Community pharmacists may never know whether medications are being taken as intended or are 235 
effective for home delivery patients. The dMUR study highlighted some of the varied difficulties 236 
facing older housebound patients often with multiple chronic conditions and unmet social care 237 
requirements. Some patients had limited contact with HCPs and did not receive the necessary care. 238 
The study showed how community pharmacists may be a link in the care pathway to help integrate 239 
many aspects of care for older, isolated, housebound patients with multiple-morbidities. This may 240 
consist of understanding the patient’s medication and care needs in the context of their home 241 
environment, providing missing medication support to carers and family members, helping to 242 
optimise patients’ medication and making referrals as appropriate. No single service can maintain 243 
patient independence alone, therefore, the establishment of relationships with all local 244 
stakeholders, including pharmacists to promote collaborative working is in the interest of the 245 
wellbeing of patients.    246 
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 Appendix A 350 
Domiciliary Medicine Support Service 351 
 352 
Patient NHS number: Pharmacist completing  
the review:  
Date of review: Pharmacy name and address: 
 
GP practice  
Please list all current medication and form, include over the counter medications, herbal 
remedies. Note who is responsible for administrating the medication 
Name of medication and form Dose Person responsible for administration 
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ACCESS ISSUES 353 
CRITERIA RESPONSE OBSERVATION/SOLUTION 
How does the person order / collect 
prescriptions? 
 
  
Do they remember to order their 
medications? 
 
 
  
Have they recently run out of any 
medications? 
 
  
Do they order all medications 
together or at different times? 
 
  
 
 
  
Solution suggestions: Prescription ordering, collection, delivery services, prescription 354 
synchronisation 355 
PHYSICAL ISSUES 356 
CRITERIA RESPONSE OBSERVATION/SOLUTION 
Can the person read all the labels? 
 
  
Can they open and close all  
containers? 
 
  
Dexterity – able to push tablets out 
of blisters, pick up small tablets, 
halve tablets? 
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Can they measure any liquid 
medicines? 
 
  
Inhalers / eyedrops – check 
technique / able to administer 
correctly? 
 
  
Are they able to swallow all their 
medicines? 
 
  
Is the medication stored 
appropriately? 
 
  
 
 
  
Solution suggestions: Large labels/symbols/colour coding, large bottles, easy open lids, pop 357 
blistered tablets into bottle, halve tablets, spacer, Haleraid, eyedrop dispenser, measuring cup, 358 
oral syringe, different formulation, advice on storage.   359 
COGNITIVE ISSUES 360 
CRITERIA RESPONSE OBSERVATION/SOLUTION 
Is the person aware of time and 
place? 
 
 
  
Does the person sometimes forget 
to take medicines? 
 
 
  
What systems do they use to remind 
them to take their medicines? 
 
 
  
Does someone help them to take 
their medicines? Who? 
 
  
Does this person prompt or actually 
administer? 
 
  
Are they able to help with all does 
on all days? Check 
weekends/evenings? 
 
  
Does the person have a compliance 
aid already? Who fills it? 
 
  
Who initiated it?   
What condition is it in? (Clean, 
labelled, legible?) 
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What about ‘prn’ medicines or 
medicines unstable in compliance 
aid? 
 
 
  
 
 
 
 
  
Solution suggestions: Reminder chart, MAR chart, link medicines to daily routine, 361 
multicompartment compliance aid 362 
 363 
 364 
 365 
 366 
 367 
CLINICAL ISSUES 368 
CRITERIA RESPONSE OBSERVATION/SOLUTION 
Is the person experiencing side 
effects? 
 
 
 
  
Are the medicines effective, does 
the patient still experience 
symptoms? 
 
 
  
Is the patient taking the right does? 
 
  
Check the OTC / herbal supplement/ 
medications- interactions. 
Duplications? 
 
 
 
 
  
 
 
  
Solution suggestions: Advise how to reduce side effects with timing, food. Discuss possible dose 369 
alterations with GP, advise about OTC medications 370 
 371 
BELIEFS ABOUT MEDICATIONS 372 
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CRITERIA RESPONSE OBSERVATION/SOLUTION 
What does the person know about 
their medicine and condition? 
 
  
What worries them about their 
medicine? 
 
 
 
  
What would they like their medicine 
to do for them? 
 
 
  
What have they decided to do about 
taking their medicine? 
 
  
 
 
 
  
Solution suggestions: Educate the person about medicines and condition, get person to decide how 373 
to fit their medicines into their daily routine and how to monitor the benefits 374 
GENERAL HOUSEKEEPING 375 
CRITERIA RESPONSE OBSERVATION/SOLUTION 
Has the house/residence been 
maintained? 
 
 
 
 
 
  
Is the patient mobile enough to use 
the premises? 
 
 
 
  
In general housekeeping within 
reasonable standards? 
 
 
 
  
Who does the housekeeping? 
 
 
  
Who cooks the meals? 
 
 
  
Has any of these any impact on the 
medical condition of the patient? 
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Has any of these any impact on the 
medication or compliance of the 
patient? 
 
 
 
  
 
 
 
  
Look for clues which may inhibit compliance, e.g. person immobile and toilet upstairs, fridge in use 376 
but food kept outside, are the feeds /insulin / fridge items in the fridge once opened….. 377 
 378 
State of Health Notes Action omment 
Dementia 
 
   
Any other condition? 
 
 
   
SOCIAL ISSUES 379 
 Notes Action  Comment 
General Environment 
 
 
 
 
   
Clutter- preventing 
falls 
 
 
 
 
   
General hygiene- 
preventing infection 
 
 
 
 
   
Meals- regular- 
helping nutrition 
 
 
 
 
   
Food storage 
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Bathroom, toilet and 
washing facilities – 
any difficulty in using 
these facilities – how 
could they be 
improved? 
 
 
 
 
 
   
Any other 
observation? 
 
 
 
 
 
 
 
   
MEDICINES FOR DISPOSAL 380 
Persons NHS number………………………………….. 381 
 382 
Name of pharmacy…………………………………………………………………….. 383 
 384 
Please list medications taken for disposal 385 
Name of medication Approximate quantity Reason disposal 
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 386 
I agree to the above medication being removed for safe disposal by the pharmacist 387 
 388 
Signature of the patient………………………………………………………………… 389 
Signature of the pharmacist ………………………………………………………. 390 
Date……………………………. 391 
COMMUNITY PHARMACY DOMICILIARY MEDICINE SUPPORT SERVICE REVIEW 392 
CARER COMMUNICATION FORM 393 
 394 
Dear Carer, 395 
Following a medicines use review, some issues have been identified. Here is a 396 
summary of the things I have put in place to address them. Please contact me 397 
on the telephone below if you wish to discuss anything further. 398 
Pharmacy Name and Address: 
 
 
 
 
Pharmacist completing  
the review:  
Date of review: Pharmacy telephone number: 
 
Persons name: 
Issue Identified Intervention made 
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COMMUNITY PHARMACY DOMICILIARY MEDICINE SUPPORT SERVICE 399 
FEEDBACK 400 
 401 
Date of visit: 402 
 403 
The visit by the pharmacist was useful          Yes / No 404 
I am more informed about my medicines    Yes / No 405 
I would recommend this service to other people   Yes / No 406 
Please add any other additional comments below 407 
 408 
 409 
 410 
 411 
 412 
 413 
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 414 
 415 
Thank you for your feedback 416 
 417 
 418 
 419 
 420 
 421 
 422 
 423 
